IVVD Invivyd, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1832038 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.3%
TTM net income YoY-117.7%
TTM EPS YoY15.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-224.4%
Net margin-214.8%
FCF margin-221.0%
EBITDA margin—
Returns
ROE-107.0%
ROA-80.7%
ROIC (approx.)-668.6%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets18.2%
Debt / equity0.00x
Current ratio5.51x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.2%
Payout ratio—
Capex / revenue3.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $15.45M | $14.29M | $13.74M | $17.21M | $13.13M | $11.79M | $11.30M | $13.82M |
| R&D expense | $18.74M | $29.37M | $30.73M | $10.05M | $8.05M | $9.57M | $10.64M | $17.91M |
| SG&A expense | $30.35M | $29.46M | $25.12M | $18.57M | $15.02M | $16.59M | $16.75M | $14.41M |
| Operating income | -$34.68M | -$45.82M | -$43.14M | -$12.55M | -$11.02M | -$15.06M | -$16.92M | -$19.23M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.47M | -$44.39M | -$41.40M | -$11.07M | -$10.47M | -$14.66M | -$16.29M | -$18.44M |
| EPS (basic) | -0.10 | -0.14 | -0.13 | — | -0.06 | -0.12 | -0.14 | — |
| EPS (diluted) | -0.10 | -0.14 | -0.13 | — | -0.06 | -0.12 | -0.14 | — |
| Weighted avg. shares (diluted) | 322.43M | 320.44M | 309.67M | — | 170.17M | 120.02M | 119.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $126.40M | $160.08M | $184.15M | $226.69M | $84.97M | $34.91M | $48.08M | $69.35M |
| Receivables | $12.19M | $11.22M | $11.65M | $13.92M | $9.85M | $8.70M | $8.56M | $10.91M |
| Inventory | — | — | — | — | $25.39M | $25.44M | $25.42M | $25.91M |
| Current assets | $147.85M | $182.11M | $204.91M | $247.47M | $109.77M | $59.28M | $75.83M | $100.68M |
| PP&E, net | $2.48M | $2.18M | $1.69M | $1.36M | $1.26M | $1.39M | $1.52M | $1.51M |
| Total assets | $183.91M | $218.88M | $241.74M | $276.88M | $139.16M | $89.14M | $103.74M | $129.51M |
| Current liabilities | $26.81M | $31.03M | $31.66M | $34.16M | $44.50M | $44.45M | $49.59M | $61.98M |
| Total liabilities | $33.42M | $37.80M | $38.69M | $35.34M | $46.09M | $46.35M | $49.59M | $61.98M |
| Shareholders' equity | $150.48M | $181.08M | $203.05M | $241.54M | $93.07M | $42.79M | $54.15M | $67.54M |
| Shares outstanding | 295.63M | 294.76M | 282.80M | 281.99M | 214.41M | 120.14M | 119.96M | 119.84M |
| Cash flow statement | ||||||||
| Operating cash flow | -$32.11M | -$43.01M | -$41.71M | -$15.46M | -$8.25M | -$13.30M | -$21.13M | -$37.61M |
| Capital expenditure | $585,000 | $510,000 | $726,000 | $0 | $0 | $11,000 | $144,000 | -$5,000 |
| Free cash flow | -$32.70M | -$43.52M | -$42.44M | -$15.46M | -$8.25M | -$13.31M | -$21.27M | -$37.60M |
| Investing cash flow | -$585,000 | -$510,000 | -$726,000 | $0 | $0 | -$11,000 | -$144,000 | $5,000 |
| Financing cash flow | $28,000 | $19.44M | -$98,000 | $157.18M | $58.31M | $131,000 | $10,000 | $77,000 |
| Stock-based compensation | $2.74M | $2.90M | $2.70M | $2.56M | $3.07M | $3.18M | $2.83M | $3.06M |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 25 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.